Non-peptide

Trevogrumab

Also known as

REGN1033 · anti-GDF8 antibody · anti-myostatin mAb COURAGE · trevogrumab Regeneron

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	An investigational antibody, also called REGN1033, that binds myostatin, a signal limiting muscle growth. Communities discuss keeping muscle during GLP-1 weight loss and possible bodybuilding gains.
Different constructs	Garetosmab blocks activin A, while FLGR-242, follistatin constructs and bimagrumab are other identities. Their amounts and timing do not transfer to trevogrumab.

Notes

Different targets. Myostatin (GDF8) limits muscle growth. Trevogrumab binds it; Garetosmab blocks activin A. These large antibodies act throughout the body, differ from testosterone, and combination results cannot isolate either drug. Regeneron: complete 26-week COURAGE results presented at EASD (Official context · Accessed 2026-09-30)

Trevogrumab (REGN1033) is an investigational myostatin-blocking antibody. Communities discuss muscle preservation during GLP-1 weight loss and possible bodybuilding gains. One poster reports enthusiasm alongside severe pain; product identity and causation are unverified.

Antibody, peptide and gene-therapy claims are different identities. Discussion compares it with FLGR-242, follistatin constructs and bimagrumab, but those names do not describe interchangeable products. The clinical subcutaneous form goes under the skin. A vial labeled REGN1033 does not establish that it matches the manufactured trial antibody, its strength or its formulation.

Source context — Regeneron: complete 26-week COURAGE results presented at EASD: Manufacturer press report, not independent replication, personal experience or full trial publication. Initial web open exposed page metadata; subsequent web calls failed 403/internal errors. A successful direct urllib HTML extraction inspected identity, 200/400-mg arms, safety/deaths and week-52 paragraphs. A subsequent direct response lacked usable text; numeric lean-mass table retains frozen source-bound provenance rather than being claimed newly rechecked. No antibody administration interval was recovered; weekly semaglutide is not antibody half-life.

What people notice

One bodybuilding account	One poster claimed added tissue and unusual difficulty gaining fat during a second REGN1033 run. The same person repeatedly reported deep or debilitating pain; product identity and changes were unverified.
Muscle-preservation interest	Human obesity-trial discussion concerns less lean-mass loss with semaglutide. This does not establish muscle gains in healthy lifters; skeptical opinions in the threads are not measured nonresponse diaries.

Notes

One enthusiastic bodybuilding account. In June 2026, Bolan claimed added tissue and unusual difficulty gaining fat during a second REGN1033 run. That is an unverified personal impression, without body-composition measurements or an isolated treatment comparison. Intro to New Wave of Myostatin Inhibitors — enthusiasm and restraint (Community discussion · Accessed 2026-09-30)

Enthusiasm and pain occur in the same account. Bolan reported at least two weeks of deep pain in December 2025, then debilitating pain in week three of his second run in May 2026. His later praise does not erase the recurrence. Trevogrumab — Bolan's early pain and persistence claims (Personal report · Accessed 2026-09-30) · Trevogrumab page 2 — repeat-run pain and loading-phase change (Personal report · Accessed 2026-09-30)

Keeping more muscle while losing weight. Biohackers discuss a better balance of fat loss and lean-tissue loss during semaglutide use. Some imagine the same approach for age-related wasting or paralysis. These are different goals from making a healthy lifter larger; discussion of the latter often extrapolates from animals. These new drugs for myostatin inhibition are going to be a game changer (Community discussion · Accessed 2026-09-30)

26-week lean mass loss. Semaglutide alone: −6.5%; with trevogrumab 200 mg: −3.3%; with 400 mg: −3.8%; garetosmab triplet: −2.0%. These obesity results do not establish healthy-lifter gains. Regeneron: complete 26-week COURAGE results presented at EASD (Official context · Accessed 2026-09-30)

Some readers want to wait, rather than become early adopters. Skud008 wanted established practice and a better-understood risk profile. Elsewhere, MPMD commenters questioned recreational usefulness. Those are skeptical opinions, not reports of taking trevogrumab and finding no benefit; no credible unchanged-response diary emerged in this sample. Intro to New Wave of Myostatin Inhibitors — enthusiasm and restraint (Community discussion · Accessed 2026-09-30) · Trevogrumab — dose repetition and recreational skepticism (Secondhand community claim · Accessed 2026-09-30)

Source context — Intro to New Wave of Myostatin Inhibitors — enthusiasm and restraint: Bolan is the same poster as early/follow-up sources. No verified identity or objective measurements. The 8800-kcal wording is ambiguous and was omitted, not converted to a daily intake. Promotional signatures and vendor advertisements warrant caution; no financial relationship proven.

Source context — Trevogrumab — Bolan's early pain and persistence claims: Anonymous self-use claim; no verified product, dose, assays or isolated co-use history. Pain explanation and persistence are assertions. Sponsor-heavy forum. Same Bolan account as the follow-up and June sources, not three users. Page 1 and page 2 share one source family/200-word allowance.

Source context — Trevogrumab page 2 — repeat-run pain and loading-phase change: Same user as December/January and June account; no independent replication, quantities, standardized outcomes or established break between runs. Excluded buying/negotiating details, irrelevant personal material and IV anecdotes about other drugs.

Source context — These new drugs for myostatin inhibition are going to be a game changer: Mechanistic speculation and retold trial/animal data; credentials unverified; no personal trevogrumab outcome diary. Some commenters make errors about sample sizes/animal species. Neither assertions of cardiac harm nor safety were adopted as established fact. Relative timestamps only; no inferred exact publication date.

Source context — Trevogrumab — dose repetition and recreational skepticism: No primary citation for schedule or self-use. Relative timestamps only on inspected body (7mo/6mo); not converted into exact dates. Speculative cost arithmetic omitted. Opinion that it is useless is not measured nonresponse.

Doses people talk about

100 mg weekly claim	A commenter presents 100 mg SubQ weekly for ten weeks as studied dosing, without a supporting trial link or self-use report. This is a circulated claim, without an established community norm.
Different 10–100 mg claim	Another explainer claims 10–100 mg SubQ every two to four weeks and attributes it to COURAGE. It documents no self-use and conflicts with the recorded trial-arm amounts.
Actual recorded trial amounts	COURAGE paired subcutaneous trevogrumab 200 or 400 mg with semaglutide 2.4 mg weekly. The antibody administration interval was not recovered; the weekly calendar belongs to semaglutide.

Notes

100 mg subcutaneous weekly for ten weeks is a circulated claim. OtherTon presents this as a studied schedule in r/moreplatesmoredates, without a supporting trial link or personal-use account. It is a claimed amount per weekly administration, not an established daily dose or community norm. Trevogrumab — dose repetition and recreational skepticism (Secondhand community claim · Accessed 2026-09-30)

10–100 mg every two to four weeks is a separate claim. An r/ChinesePeptides explainer attributes this subcutaneous range to COURAGE. It conflicts with the trial-arm amounts below and does not document self-use. Keep these claims separate rather than combining them into a dose range. The Next Leap in Body Composition — monkey-to-human projections (Secondhand community claim · Accessed 2026-09-30)

September 2025 COURAGE amounts. Subcutaneous trevogrumab 200 or 400 mg was paired with weekly semaglutide 2.4 mg. These amounts establish neither circulated antibody schedule. Regeneron: complete 26-week COURAGE results presented at EASD (Official context · Accessed 2026-09-30)

September 17, 2025 press report: identity/combination arms, lean-mass table, tolerability/deaths paragraph and week-52 follow-up. Exact table values and SC/weekly-semaglutide context additionally retained from frozen profile reported_benefits[0], dosing_ranges_reported[1–2], delivery_methods[0], dose_bands[0–1] and timing_summary.sources[0]. Regeneron: complete 26-week COURAGE results presented at EASD (Official context · Accessed 2026-09-30)

Source context — The Next Leap in Body Composition — monkey-to-human projections: Synthetic projections, not a human log. Schedule conflicts with COURAGE arm amounts; unsupported trial attribution. Original author/date not exposed in inspected text beyond relative 1y timestamp. This is community retelling of animal/manufacturer results, not independent efficacy evidence.

Half-life, onset & duration

Felt onset	No useful first noticeable strength, fullness or physique timeline is established. A 26-week trial assessment cannot show the first effective day.
Felt duration	One poster claims continued myostatin blocking up to three months after the last injection, without testing or a dated benefit timeline. A reliable gym-effect window is unknown.
Half-life	No measured community value is established here. The 19-day number in comparison talk concerns FLGR, a different construct; weekly GLP-1 use does not measure antibody clearance.

Notes

A useful onset clock is still missing. No dated first noticeable strength, fullness or physique change was identified. A trial assessment at 26 weeks does not show when a benefit first began.

Up to three months after the last injection is one poster's claim. Bolan claims continued myostatin blocking without testing or a dated benefit timeline. This is unverified persistence, not blood half-life or a reliable gym-effect duration. Trevogrumab — Bolan's early pain and persistence claims (Personal report · Accessed 2026-09-30)

No measured community half-life identified. The 19-day figure mentioned in FLGR comparison talk belongs to another construct. Neither a weekly GLP-1 calendar nor reported persistence of effects measures how quickly trevogrumab leaves the blood.

Cycles people discuss

One changing course	The main poster extended a second loading phase from five to ten weeks, without a reproducible mg schedule or a stated break before repeating. Follistatin and FLGR calendars concern other constructs.

Notes

Five weeks, then ten weeks in one account. Bolan extended his second loading phase from five to ten weeks. No reproducible mg schedule or break before repeating is supplied; this does not establish a general cycle. Trevogrumab page 2 — repeat-run pain and loading-phase change (Personal report · Accessed 2026-09-30)

Follistatin and FLGR calendars do not transfer. The discussed 10–30-day FS-344 courses and 12–16-week FLGR blocks concern other constructs. A COURAGE follow-up period likewise does not establish a bodybuilding cycle.

Stacks

COURAGE combinations	The semaglutide/trevogrumab pair differs from the triplet adding garetosmab. Combination trial outcomes cannot isolate each antibody's contribution or validate a gray-market stack.

Notes

Preserving muscle is the original appeal. GLP-1 discussion frames trevogrumab as avoiding muscle loss while dieting, and uses it as a comparison for FLGR's different pathway claims. That purpose is narrower than promising rapid muscle gain, and the semaglutide pair differs from the garetosmab triplet.

+ Semaglutide is the COURAGE pair people screenshot. [trial]

Garetosmab triplet: Adding the activin-A antibody creates a different trial combination. The saved report describes more discontinuations and two triplet deaths, for which Regeneron reported no identified causal association. [trial]

Watch for

Repeated severe pain	The main poster described at least two weeks of deep pain in one run and debilitating pain in week three of another. Their belief that pain meant muscle growth is unverified.
Combination safety	The COURAGE report describes more people stopping treatment and two deaths in the three-drug group. Regeneron said it had not found a link between the treatment and the deaths.
Identity and promotion	A labeled vial, high price or confident testimonial does not establish the trial antibody's contents or strength. Vendor advertising and promotional signatures accompany parts of the discussion.

Notes

Deep pain is not proof of productive growth. Bolan's explanation that pain meant growing muscle is unverified. Debilitating pain remains an adverse report despite his enthusiasm. Trevogrumab — Bolan's early pain and persistence claims (Personal report · Accessed 2026-09-30) · Trevogrumab page 2 — repeat-run pain and loading-phase change (Personal report · Accessed 2026-09-30)

More discontinuations and two triplet deaths. Regeneron identified no causal association. Maintenance tested higher-dose trevogrumab or placebo through week 52. Regeneron: complete 26-week COURAGE results presented at EASD (Official context · Accessed 2026-09-30)

Less lean-mass loss does not mean stronger tendons or a safer heart. Biohackers debate tendon injury and heart enlargement, with conflicting interpretations and animal arguments. These discussions identify unresolved concerns, not demonstrated event rates or assurances that this antibody avoids steroid risks. Long-term use and combinations remain uncertain. These new drugs for myostatin inhibition are going to be a game changer (Community discussion · Accessed 2026-09-30)

Commercial confidence cannot verify the contents. The discussions occur in communities with vendor advertising and promotional signatures. A confident user, high price or familiar research name does not verify antibody identity. Trial findings cannot validate an unrelated vial or an improvised combination. Intro to New Wave of Myostatin Inhibitors — enthusiasm and restraint (Community discussion · Accessed 2026-09-30)

Full notes

What Trevogrumab is

Different targets. Myostatin (GDF8) limits muscle growth. Trevogrumab binds it; Garetosmab blocks activin A. These large antibodies act throughout the body, differ from testosterone, and combination results cannot isolate either drug. Official context Community
Antibody, peptide and gene-therapy claims are different identities. Discussion compares it with FLGR-242, follistatin constructs and bimagrumab, but those names do not describe interchangeable products. The clinical subcutaneous form goes under the skin. A vial labeled REGN1033 does not establish that it matches the manufactured trial antibody, its strength or its formulation. Community

Why people are interested

Keeping more muscle while losing weight. Biohackers discuss a better balance of fat loss and lean-tissue loss during semaglutide use. Some imagine the same approach for age-related wasting or paralysis. These are different goals from making a healthy lifter larger; discussion of the latter often extrapolates from animals. Reddit r/Biohackers
One enthusiastic bodybuilding account. In June 2026, Bolan claimed added tissue and unusual difficulty gaining fat during a second REGN1033 run. That is an unverified personal impression, without body-composition measurements or an isolated treatment comparison. Anabolic Steroid Forums

Doses people discuss

100 mg subcutaneous weekly for ten weeks is a circulated claim. OtherTon presents this as a studied schedule in r/moreplatesmoredates, without a supporting trial link or personal-use account. It is a claimed amount per weekly administration, not an established daily dose or community norm. Reddit r/moreplatesmoredates
10–100 mg every two to four weeks is a separate claim. An r/ChinesePeptides explainer attributes this subcutaneous range to COURAGE. It conflicts with the trial-arm amounts below and does not document self-use. Keep these claims separate rather than combining them into a dose range. Reddit r/ChinesePeptides

Half-life claims

No measured community half-life identified. The 19-day figure mentioned in FLGR comparison talk belongs to another construct. Neither a weekly GLP-1 calendar nor reported persistence of effects measures how quickly trevogrumab leaves the blood. Community

When effects become noticeable

A useful onset clock is still missing. No dated first noticeable strength, fullness or physique change was identified. A trial assessment at 26 weeks does not show when a benefit first began. Community

How long effects may last

Up to three months after the last injection is one poster's claim. Bolan claims continued myostatin blocking without testing or a dated benefit timeline. This is unverified persistence, not blood half-life or a reliable gym-effect duration. Personal report

Courses and repeat-use talk

Five weeks, then ten weeks in one account. Bolan extended his second loading phase from five to ten weeks. No reproducible mg schedule or break before repeating is supplied; this does not establish a general cycle. Personal report
Follistatin and FLGR calendars do not transfer. The discussed 10–30-day FS-344 courses and 12–16-week FLGR blocks concern other constructs. A COURAGE follow-up period likewise does not establish a bodybuilding cycle. Community

Good to know

Deep pain is not proof of productive growth. Bolan's explanation that pain meant growing muscle is unverified. Debilitating pain remains an adverse report despite his enthusiasm. Personal report Personal report
Less lean-mass loss does not mean stronger tendons or a safer heart. Biohackers debate tendon injury and heart enlargement, with conflicting interpretations and animal arguments. These discussions identify unresolved concerns, not demonstrated event rates or assurances that this antibody avoids steroid risks. Long-term use and combinations remain uncertain. Reddit r/Biohackers
Commercial confidence cannot verify the contents. The discussions occur in communities with vendor advertising and promotional signatures. A confident user, high price or familiar research name does not verify antibody identity. Trial findings cannot validate an unrelated vial or an improvised combination. Community Anabolic Steroid Forums

The human trial behind the discussion

September 2025 COURAGE amounts. Subcutaneous trevogrumab 200 or 400 mg was paired with weekly semaglutide 2.4 mg. These amounts establish neither circulated antibody schedule. Official context
26-week lean mass loss. Semaglutide alone: −6.5%; with trevogrumab 200 mg: −3.3%; with 400 mg: −3.8%; garetosmab triplet: −2.0%. These obesity results do not establish healthy-lifter gains. Official context
More discontinuations and two triplet deaths. Regeneron identified no causal association. Maintenance tested higher-dose trevogrumab or placebo through week 52. Official context

What the community discussion adds

Enthusiasm and pain occur in the same account. Bolan reported at least two weeks of deep pain in December 2025, then debilitating pain in week three of his second run in May 2026. His later praise does not erase the recurrence. Personal report Personal report
Some readers want to wait, rather than become early adopters. Skud008 wanted established practice and a better-understood risk profile. Elsewhere, MPMD commenters questioned recreational usefulness. Those are skeptical opinions, not reports of taking trevogrumab and finding no benefit; no credible unchanged-response diary emerged in this sample. Anabolic Steroid Forums Reddit r/moreplatesmoredates
Animal projections can look like impressive human results. One ChinesePeptides post scales monkey fat and muscle changes to a hypothetical 210-lb man, including a projected 22.5-lb muscle gain with the triplet. That is arithmetic applied to animal results, not a person's before-and-after log or a prediction readers can rely on. Reddit r/ChinesePeptides
The dispute is about what the results actually mean. In r/Biohackers, replies distinguish animal muscle gains from human lean-mass preservation and challenge claims of few side effects. The useful takeaway is the disagreement itself: selective signaling does not establish a harmless replacement for steroids or unlimited growth. Reddit r/Biohackers
Preserving muscle is the original appeal. GLP-1 discussion frames trevogrumab as avoiding muscle loss while dieting, and uses it as a comparison for FLGR's different pathway claims. That purpose is narrower than promising rapid muscle gain, and the semaglutide pair differs from the garetosmab triplet. Community